Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Site-directed tumor chemotherapy.

R Arnon

    Comprehensive Therapy
    |April 1, 1978
    PubMed
    Summary
    This summary is machine-generated.

    Drug-antibody conjugates enhance cancer chemotherapy by targeting tumors. These targeted drug delivery systems show improved efficacy and survival rates in preclinical models compared to free drugs.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    [50] Reaction with N-carboxy-α-amino acid anhydrides.

    Methods in enzymology·2012
    Same author

    Anti-lymphocyte therapy successfully controls late "cholestatic" rejection in pediatric liver transplant recipients.

    Clinical transplantation·2011
    Same author

    Stevens-Johnson syndrome after Mycoplasma pneumonia infection in pediatric post-liver transplant recipient: case report and review of the literature.

    Pediatric transplantation·2010
    Same author

    Glatiramer acetate (GA, Copolymer-1) an hypothetical treatment option for Rett syndrome.

    Medical hypotheses·2010
    Same author

    A universal epitope-based influenza vaccine and its efficacy against H5N1.

    Vaccine·2009
    Same author

    Antibodies to glatiramer acetate do not interfere with its biological functions and therapeutic efficacy.

    Multiple sclerosis (Houndmills, Basingstoke, England)·2003
    Same journal

    Heparin-induced thrombocytopenia and thrombosis.

    Comprehensive therapy·2011
    Same journal

    Antiplatelet therapy in cardiovascular disease.

    Comprehensive therapy·2011
    Same journal

    Genetics of cardiovascular disease.

    Comprehensive therapy·2011
    Same journal

    Septic renal vein thrombosis complicated by septic pulmonary embolism.

    Comprehensive therapy·2011
    Same journal

    Gout and hyperuricemia.

    Comprehensive therapy·2011
    Same journal

    Problems with computerized health records.

    Comprehensive therapy·2011
    See all related articles

    Area of Science:

    • Oncology
    • Pharmacology
    • Biotechnology

    Background:

    • Chemotherapeutic drug efficacy is often limited by systemic toxicity and poor tumor targeting.
    • Macromolecular carriers offer a strategy to improve drug delivery and therapeutic outcomes in cancer treatment.

    Purpose of the Study:

    • To investigate the therapeutic potential of conjugating the chemotherapeutic drug daunomycin to macromolecular carriers, specifically antitumor antibodies.
    • To evaluate the in vitro and in vivo efficacy of these drug-antibody conjugates compared to unconjugated drugs and other carrier systems.

    Main Methods:

    • Daunomycin was chemically linked to antitumor antibodies, either directly or via a dextran linker.
    • In vitro cytotoxicity assays were performed on tumor cells recognized by the antibodies.

    Related Experiment Videos

  • In vivo studies involved administering conjugates to mice transplanted with tumor cells to assess survival rates.

    • Main Results:

    • Daunomycin-antibody conjugates retained both antibody-specific targeting and drug cytotoxic activity.
    • These conjugates demonstrated enhanced therapeutic efficacy in vivo, prolonging survival in tumor-bearing mice.
    • Drug-antibody conjugates showed an advantage over free drugs and other carrier conjugates, particularly at lower drug concentrations.

    Conclusions:

    • Conjugating daunomycin to antitumor antibodies represents a promising strategy for targeted cancer chemotherapy.
    • Drug-antibody conjugates offer improved therapeutic efficacy and reduced toxicity by delivering the drug specifically to tumor cells.
    • Further research into drug-carrier systems, especially antibody conjugates, is warranted for optimizing cancer treatment.